Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure†
There are no financial disclosures to report. There has been no financial support in preparation of this report. The authors have no commercial or proprietary interest in any drug, device, or equipment mentioned in this report.
Abstract
Intravenous continuous infusion of betalactam (CIBL) antibiotic and high dose extended interval (HDEI) aminoglycoside therapy theoretically maximize bacterial killing in treatment of Pseudomonas aeruginosa (PsA) in pulmonary exacerbations of cystic fibrosis (CF). We present the case of a 3-month-old female infant with CF who failed outpatient eradication of PsA with subsequent eradication using intravenous CIBL antibiotic and HDEI aminoglycoside therapy. This antibiotic combination should be considered in order to optimize pharmacodynamics for PsA eradication in CF patients before development of chronic colonization. Pediatr Pulmonol. 2008; 43:511–513. © 2008 Wiley-Liss, Inc.
